Article
Biochemistry & Molecular Biology
Martina Burlando, Gabriella Fabbrocini, Claudio Marasca, Paolo Dapavo, Andrea Chiricozzi, Dalma Malvaso, Valentina Dini, Anna Campanati, Annamaria Offidani, Annunziata Dattola, Raffaele Dante Caposiena Caro, Luca Bianchi, Marina Venturini, Paolo Gisondi, Claudio Guarneri, Giovanna Malara, Caterina Trifiro, Piergiorigio Malagoli, Maria Concetta Fargnoli, Stefano Piaserico, Luca Carmisciano, Riccardo Castelli, Aurora Parodi
Summary: This study compared the effectiveness of adalimumab originator and biosimilar in HS patients, and found that the biosimilar group had a greater loss of efficacy. Switching from one drug to the other may increase the risk of treatment ineffectiveness.
Article
Dermatology
L. M. Prens, K. Bouwman, P. Aarts, S. Arends, K. R. van Straalen, K. Dudink, B. Horvath, E. P. Prens
Summary: This study evaluated the drug survival of antitumour necrosis factor biologics for patients with hidradenitis suppurativa in daily practice. Survival rates for adalimumab and infliximab were similar at 12 months, mainly determined by ineffectiveness. Age, disease duration (adalimumab), and surgery (infliximab) were identified as predictors for longer drug survival.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Article
Dermatology
A. Hafner, P. D. Ghislain, R. Kovacs, R. Batchelor, A. C. Katoulis, B. Kirby, H. Banayan, M. Schonbrun
Summary: Treatment with adalimumab in patients with moderate-to-severe hidradenitis suppurativa resulted in significant improvements in disease severity, quality of life, and work productivity, with a rapid and sustained response over 52 weeks. No unexpected safety signals were reported.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Dermatology
Pim Aarts, Johanna C. van Huijstee, Hessel H. van der Zee, Martijn B. A. van Doorn, Kelsey R. van Straalen, Errol P. Prens
Summary: This study compared the clinical effectiveness of combining surgery with adalimumab to adalimumab monotherapy in patients with moderate to severe hidradenitis suppurativa. The results showed that after 12 months of treatment, the combination group had a significantly greater reduction in the International Hidradenitis Suppurativa Severity Score System and Dermatology Life Quality Index compared to the monotherapy group. However, the study's follow-up period was too short to assess surgical recurrence rates.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Dermatology
Y. Cao, F. Hong, D. M. Conlon, L. Sidur, K. M. Smith, Y. Fang, C. A. Cuff, Z. Kaymakcalan, M. C. Ruzek
Summary: This study identified potential predictive biomarkers, including HCC-4, calprotectin, and fractalkine, for adalimumab response in patients with hidradenitis suppurativa (HS), as well as possible tumor necrosis factor-independent disease pathways. Additionally, it found that certain cytokines involved in inflammatory responses may contribute to disease drivers in adalimumab nonresponders.
BRITISH JOURNAL OF DERMATOLOGY
(2021)
Review
Dermatology
Gregor B. E. Jemec, Veronique del Marmol, Vincenzo Bettoli, Matthias Augustin, Errol P. Prens, Christos C. Zouboulis
Summary: The European Hidradenitis Suppurativa Foundation is taking initiatives for collaborative studies in order to accelerate research and drug discovery for Hidradenitis Suppurativa. These studies include multicentre research and genetic studies.
EXPERIMENTAL DERMATOLOGY
(2022)
Article
Dermatology
W. Gulliver, A. Alavi, M. C. Wiseman, M. J. Gooderham, J. Rao, M. S. Alam, K. A. Papp, O. Desjardins, C. Jean
Summary: The study found that patients with moderate and high AN counts achieved better results at 24 and 52 weeks of treatment with adalimumab, with gender and age at onset affecting treatment effectiveness. The use of adalimumab led to a decrease in lesions, especially in inflammatory nodules, and the IHS4 scores of responders were substantially lowered. No new safety issues were detected during the treatment and observation period.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Medicine, General & Internal
Fabrizio Martora, Claudio Marasca, Vincenzo Picone, Luigi Fornaro, Matteo Megna, Gabriella Fabbrocini
Summary: We conducted a one-year prospective study involving 58 patients with Hidradenitis Suppurativa. By retrospectively analyzing data and comparing it to the year before starting adalimumab, an anti-TNF alpha drug, we aimed to assess how this biologic therapy affects antibiotic therapy, flare-ups frequency and duration, as well as patients' quality of life and perceived pain.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Dermatology
Pelin Esme, Gulsen Akoglu, Cansu Dogan Dalkiran, Ercan Caliskan
Summary: This study investigated the role of certolizumab pegol in treating severe and recalcitrant hidradenitis suppurativa (HS) patients who were unresponsive to adalimumab. The results showed that certolizumab pegol had a promising treatment effect on some patients but not all maintained response after continued therapy. Improvement in patients' dermatological life quality index and HS severity score were observed after 12 and 24 weeks of treatment.
DERMATOLOGIC THERAPY
(2022)
Article
Medicine, General & Internal
Trinidad Montero-Vilchez, Carlos Cuenca-Barrales, Andrea Rodriguez-Tejero, Antonio Martinez-Lopez, Salvador Arias-Santiago, Alejandro Molina-Leyva
Summary: The study describes the clinical experience of switching from adalimumab originator to biosimilar and back again. Switching to biosimilar can lead to efficacy and adherence issues, while switching back to the original drug can resolve most problems, though some patients may lose confidence and discontinue treatment. Evaluating the benefit-risk ratio is important when switching HS patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Letter
Dermatology
Ben Koszegi, Anna Wilson, Corey Stone, Fanny Satge, Timothy L. Cowan, Dedee F. Murrell
Summary: Our case series study found that tildrakizumab treatment led to initial improvement in disease activity within the first 6 months in hidradenitis suppurativa patients who had previously received adalimumab. However, this improvement was not sustained beyond the 6-month mark. Nevertheless, patients who had long-term follow-up on tildrakizumab showed ongoing disease activity but a reduction in Dermatology Life Quality Index scores.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)
Article
Dermatology
Tasnim Abdalla, Mark Mansour, Dorra Bouazzi, Michelle A. Lowes, Gregor B. E. Jemec, Afsaneh Alavi
Summary: This study examined serum adalimumab concentrations and anti-adalimumab antibody status in 38 patients with moderate-to-severe hidradenitis suppurativa who had suboptimal response to adalimumab therapy. The results showed that patients with anti-adalimumab antibodies had significantly lower adalimumab levels, suggesting that therapeutic drug monitoring may help identify reasons for suboptimal response and guide dose optimization strategies.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2021)
Article
Dermatology
Klasiena Bouwman, Pim Aarts, Koen Dudink, Jiasi Hao, Behrooz Z. Alizadeh, Lisette M. Prens, Allard R. J. V. Vossen, Kelsey R. van Straalen, Hessel H. van der Zee, Barbara Horvath
Summary: Cohort studies on the use of retinoids for hidradenitis suppurativa (HS) have yielded conflicting results. This study aimed to evaluate the drug survival of oral retinoids in the treatment of HS and establish predictors for longer treatment duration. The overall drug survival rates for isotretinoin and acitretin were similar at 12 months, with termination of treatment mainly due to ineffectiveness. Patients with widespread comedones and the scarring folliculitis phenotype may benefit from treatment with isotretinoin or acitretin, respectively.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
(2022)
Article
Dermatology
Alzbeta Smetanova, Emanuel Marques, Martina Kojanova, Petr Arenberger, Daniela Strosova, Jorga Fialova, Monika Arenbergerova
Summary: This multicenter observational study evaluated the effectiveness, safety, and drug survival of adalimumab in patients with moderate-to-severe hidradenitis suppurativa. The results showed that adalimumab demonstrated sustained and rapid effects in improving the condition, reducing inflammatory lesions, and enhancing patients' quality of life during the 48-month treatment period, with no unexpected risk signals observed.
DERMATOLOGIC THERAPY
(2023)
Article
Surgery
Ryoko Hamaguchi, Taylor L. Wearda, Angela S. Volk, Kimberly M. Kramer, Alexa B. Kimball, Abigail E. Chaffin, Dennis P. Orgill
Summary: This multi-institutional retrospective chart review demonstrates the effectiveness of surgery as a therapy for hidradenitis suppurativa and presents various site-specific closure techniques that can serve as a foundation for future research and guidelines.
PLASTIC AND RECONSTRUCTIVE SURGERY
(2022)
Letter
Dermatology
Luciano Ibba, Luigi Gargiulo, Casana Maddalena, Francesco Sacrini, Alessandra Narcisi, Paola Morelli, Antonio Costanzo, Luca Livio Mancini
INTERNATIONAL JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Giuseppe Micali, Anna Elisa Verzi, Maria Letizia Musumeci, Beatrice Nardone, Giuseppe Monfrecola, Francesco Lacarrubba
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Letter
Dermatology
Luca Stingeni, Leonardo Bianchi, Elettra Antonelli, Elena Sofia Caroppo, Silvia Mariel Ferrucci, Carlotta Gurioli, Michela Ortoncelli, Gabriella Fabbrocini, Eustachio Nettis, Donatella Schena, Maddalena Napolitano, Massimo Gola, Laura Bonzano, MariaTeresa Rossi, Anna Belloni Fortina, Anna Balato, Ketty Peris, Caterina Foti, Fabrizio Guarneri, Marco Romanelli, Cataldo Patruno, Paola Savoia, Maria Esposito, Filomena Russo, Enzo Errichetti, Tommaso Bianchelli, Luca Bianchi, Giovanni Pellacani, Claudio Feliciani, Annamaria Offidani, Monica Corazza, Giuseppe Micali, Nicola Milanesi, Giovanna Malara, Andrea Chiricozzi, Marta Tramontana, Katharina Hansel
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, Luciano Ibba, Fabrizio Amoruso, Giuseppe Argenziano, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Giampiero Girolomoni, Claudio Guarneri, Francesco Loconsole, Francesca Sampogna, Massimo Travaglini, Piergiorgio Malagoli, Antonio Costanzo
Summary: This retrospective study assessed the effectiveness and safety of tildrakizumab in the real-life clinical practice for treating plaque psoriasis. The results showed that a significant proportion of patients achieved PASI 75, PASI 90, and PASI 100 at 52 weeks, with higher percentages achieving complete skin clearance. No significant safety concerns were observed, and no patients had to discontinue treatment due to adverse events.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Claudio Fenizia, Chiara Moltrasio, Luisa Ottobrini, Olga Utyro, Giovanni Genovese, Claudia Vanetti, Daria Trabattoni, Angelo V. Marzano
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2023)
Article
Dermatology
P. Gisondi, M. Maurelli, A. Costanzo, M. Esposito, G. Girolomoni
Summary: This study aimed to investigate the safety of combining Dupilumab with other monoclonal antibodies. Through the examination of 16 cases and our clinical practice involving 8 patients, it was found that there were no adverse events related to the combination of two monoclonal antibodies, except for a few mild reactions.
DERMATOLOGY AND THERAPY
(2023)
Article
Genetics & Heredity
Chiara Moltrasio, Maurizio Romagnuolo, Davide Riva, Davide Colavito, Silvia Mariel Ferrucci, Angelo Valerio Marzano, Gianluca Tadini, Michela Brena
Summary: Netherton syndrome (NS) is a rare autosomal recessive disorder caused by SPINK5 gene mutations. A case study showed that the combination of a null heterozygous mutation and a homozygous polymorphism in the SPINK5 gene can cause NS, despite normal expression of the LEKTI protein. These findings highlight the importance of genetic testing for SPINK5 mutations in cases of clinical overlap between NS and atopic dermatitis (AD).
Article
Dermatology
Marina Talamonti, Filomena Russo, Giovanna Malara, Katharina Hansel, Manuela Papini, Angelo Cattaneo, Aurora Parodi, Andrea Chiricozzi, Piergiorgio Malagoli, Federico Bardazzi, Valeria Brazzelli, Paolo Dapavo, Paolo Gisondi, Cristina Zane, Concetta Potenza, Franca Cantoresi, Maria Concetta Fargnoli, Sara Trevisini, Pina Brianti, Leonardo Pescitelli, Giovanni Gigante, Marta Bartezaghi, Luisa Caputo, Elisabetta Aloisi, Antonio Costanzo
Summary: This study compared the efficacy and safety of Secukinumab in adult patients with plaque psoriasis versus elderly patients. The results showed that the treatment was slightly less effective in elderly patients, but there were no significant differences in anxiety and depression levels between the two groups. In conclusion, Secukinumab is a valid option for the management of moderate to severe psoriasis in elderly patients.
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
(2023)
Article
Genetics & Heredity
Marco Ritelli, Nicola Chiarelli, Valeria Cinquina, Marika Vezzoli, Marina Venturini, Marina Colombi
Summary: The most common conditions with symptomatic joint hypermobility are hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). Diagnosing these overlapping connective tissue disorders remains challenging due to the lack of established causes and reliable diagnostic tests. The effectiveness of the 2017 diagnostic criteria in distinguishing between hEDS and HSD and the frequencies of extra-articular manifestations were evaluated retrospectively in this study.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A
(2023)
Review
Biochemistry & Molecular Biology
Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, Elena Campione, Luca Bianchi
Summary: Melanoma, the deadliest form of skin cancer, accounts for almost 90% of skin cancer mortality. Despite advances in immune and targeted therapies, many patients still experience disease progression. Skin metastases, a common occurrence in melanoma, can be treated through various methods including surgery, injections, and systemic therapies. Further research is needed to understand the underlying mechanisms and differences in behavior and prognosis among melanoma patients with skin metastases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Maria Cristina Rapanotti, Elisa Cugini, Elena Campione, Cosimo Di Raimondo, Gaetana Costanza, Piero Rossi, Amedeo Ferlosio, Sergio Bernardini, Augusto Orlandi, Anastasia De Luca, Luca Bianchi
Summary: The most promising method for monitoring patients with minimal morbidity is the detection of circulating melanoma cells (CMCs). We have shown that CD45(-)CD146(+)ABCB5(+) CMCs are a rare primitive stem/mesenchymal CMCs population associated with disease progression. Investigating the gene expression of isolated CMCs' epithelial-to-mesenchymal transition (EMT) gene signature can provide potential clinical value.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Dermatology
Paolo Gisondi, Luis Puig, Marie Aleth Richard, Carle Paul, Tamar Nijsten, Charles Taieb, Alex Stratigos, Myrto Trakatelli, Carmen Salavastru
Summary: This study evaluated the burden of the most common dermatological diseases in adult patients in Europe in terms of quality of life, work life, and stigmatization. The findings revealed that skin diseases heavily impact patients' daily and work life and also cause feelings of stigmatization.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Dermatology
Marie Aleth Richard, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taieb, Myrto Trakatelli, Luis Puig, Alex Stratigos, EADV burden skin Dis project team
Summary: This study investigated the public perception of dermatologists in Europe and found that most people believe dermatologists play a crucial role in skin health and are satisfied with the service provided. Across different regions, people most commonly visit dermatologists for skin issues such as skin cancer screening, chronic skin diseases, and acute skin diseases.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Letter
Dermatology
Francesco Bellinato, Paolo Gisondi, Anna Balato, Giacomo Caldarola, Edoardo Cammarata, Elena Campione, Andrea Carugno, Andrea Conti, Monica Corazza, Paolo Dapavo, Annunziata Dattola, Vito Di Lernia, Massimo Gasperini, Salvatore Panduri, Francesca Prignano, Francesca Satolli, Enzo Spisni, Giampiero Girolomoni
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Dermatology
Tiago Torres, Jordi Galvan, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Paolo Gisondi, Jose Manuel Carrascosa, Bruno Halioua, Anthony Bewley, Andreas Pinter
Summary: Topical treatment of psoriasis is important but non-adherence is a challenge. CAL/BDP PAD-cream, based on PAD Technology, offers a more convenient and effective treatment. This formulation ensures stability, increases penetration, and improves cosmetic acceptability. Clinical trials have shown high efficacy, safety, and patient satisfaction with CAL/BDP PAD-cream, potentially leading to improved adherence and outcomes.
DERMATOLOGY AND THERAPY
(2023)